Atrogi has announced the dosing of the first subjects in its human trial for lead candidate ATR-258, which will evaluate the muscle physiological effects of its highly selective GRK-targeted β2-adrenergic signalling pathway.
The eight-week, investigator-initiated, interventional study will examine biased β2-adrenergic receptor (β2-AR) signalling in human skeletal muscle in overweight male volunteers who will receive daily oral dosing of ATR-258, Atrogi's GRK-selective, long-acting β2-agonist.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.